纤溶酶原激活物抑制剂活性及其4G/5G基因多态性与急性冠状动脉综合征发病的关系
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

湖南省卫生厅资助课题(9959)


Plasminogen Activator Inhibitor-1 Activity and It's 4G/5G Gene Polymorphism in Acute Coronary Syndrome
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的了解急性冠状动脉综合征患者血浆纤溶酶原激活物抑制剂1活性变化及其启动子4G/5G基因多态性特点,以探讨血浆纤溶酶原激活物抑制剂1及其基因多态性在急性冠状动脉综合征发病过程中的作用。方法对106例急性冠状动脉综合征患者9、8例稳定型冠心病患者和60例对照者用聚丙烯酰胺凝胶电泳寡核苷酸杂交分析法测定白细胞启动子4G/5G多态性位点的基因型,用酶联免疫吸附法测定血浆纤溶酶原激活物抑制剂1活性。结果急性冠状动脉综合征组血浆纤溶酶原激活物抑制剂1活性(18.0±2.9 kAU/L)较稳定型冠心病组(16.8±2.7 kAU/L)和对照组(16.2±2.8 kAU/L)增高(p<0.01和p<0.005);急性冠状动脉综合征组中4G/4G纯合子个体(49.1%)较稳定型冠心病组(28.6%)和对照组(26.7%)频率高(p<0.05);4G/4G纯合子个体的血浆纤溶酶原激活物抑制剂1活性最高,5G/5G个体最少(p<0.05)。结论血浆纤溶酶原激活物抑制剂1活性与启动子4G/5G基因型有关;血浆纤溶酶原激活物抑制剂1活性增高是急性冠状动脉综合征发病的危险因素之一。

    Abstract:

    Aim To investigate whether the plasma plasminogen activator inhibitor-1(PAI-1) activity and gene polymorphism played a pathogenetic role in acute coronary syndrome(ACS). Methods 106 patients suffering from acute coronary syndrome(ACS) and 98 subjects,who were suffering from stable coronary heart disease(SCHD),and 60 normal controls were recruited.The 4G/5G allele polymorphism were genotyped by using polymerase chain reaction technique,while plasma activity assayed by enzyme linked immunosorbent assay. Results The plasma PAI-1 activity level in the ACS group(18.0±2.9 kAU/L) was significantly higher than that in the SCHD group(16.8±2.7 kAU/L) and in the control group(16.2±2.8 kAU/L;p<0.01 or p<0.005).The frequency of 4G/4G allele homozygous in the ACS group(49.1%) was significantly higher than that in the SCHD group(28.6%) and in the control group(26.7%;p<0.05).The plasma PAI-1 activity level was statistically higher in 4G allele homozygous than those in 4G/5G heterozygous and 5G homozygous(p<0.05). Conclusions There may be a link between the plasma PAI-1 activity and it's 4G/5G genotype.Elevated plasma PAI-1 activity and essentially 4G allele homozygous genotype might be the major risk factors of ACS.

    参考文献
    相似文献
    引证文献
引用本文

曾高峰,刘格修,王燕,刘康桐,丁翠芬,匡希斌.纤溶酶原激活物抑制剂活性及其4G/5G基因多态性与急性冠状动脉综合征发病的关系[J].中国动脉硬化杂志,2005,13(6):760~762.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2004-12-27
  • 最后修改日期:2005-11-10
  • 录用日期:
  • 在线发布日期: